Anxiety has quietly become one of the world's most prevalent health issues. At any given time, approximately 4% to 5% of the world's population suffers from anxiety disorders. Long-term surveys in the United States indicate that roughly one-third of the population will experience an anxiety disorder at some point in their lives. However, even these figures may underestimate the situation. Across countries, stigma and underreporting make it difficult to assess the actual scope of this rising phenomenon. 

Most of us have personally experienced anxiety or know someone who has. It has an impact on relationships, careers, and overall quality of life. Although effective therapy has the potential to improve lives, innovation in this area has stagnated during the last two decades. 

According to Hannah Ritchie and Tuna Acisu's (2025) paper, "Anxiety is one of the world's most common health issues." How have therapies developed over the last 70 years?" published on OurWorldinData.org, the narrative of anxiety medication demonstrates both medical advancement and squandered chances. Since the 1950s, scientists have produced various types of medications to treat anxiety. Surprisingly, no new medications for anxiety have been licensed since 2004. 

The first breakthrough occurred in the 1950s with tranquillisers such as meprobamate (Miltown), which was dubbed America's first "blockbuster" psychiatric medicine. It calmed the nervous system and provided immediate comfort, but it had a high danger of dependence. 

Benzodiazepines, such as Valium and Xanax, rose to prominence in the 1960s and 1970s. These medications worked faster than tranquillisers and lowered anxiety by increasing GABA, a brain neurotransmitter that promotes relaxation. They were extensively prescribed and became cultural icons for modern stress reduction. However, the risk of addiction and withdrawal quickly became a concern. 

By the 1990s, medical attention had switched to antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) like fluoxetine (Prozac) and sertraline (Zoloft). These medications performed more slowly, but they provided longer-term stability and posed fewer dependency hazards. They worked by keeping serotonin levels in the brain stable, which helps to regulate mood and reduces terror responses. Later, SNRIs such as duloxetine (Cymbalta), which also affects norepinephrine, became the primary treatment for generalised anxiety. 

Despite their success, innovation has recently halted. According to Ritchie and Acisu (2025), duloxetine, which was licensed in 2004, is still the only new anxiety-specific medicine available in the United States. Since then, the emphasis has switched to enhancing existing formulations and using antidepressants "off-label" for anxiety. 

Meanwhile, research has moved beyond medications. Cognitive behavioural therapy (CBT), non-invasive brain stimulation, and even virtual reality exposure therapies have emerged as non-drug treatments. Instead of simply suppressing symptoms, these therapies seek to reprogram the brain's fear pathways. 

However, the gap between demand and effective therapy remains significant. Anxiety disorders affect hundreds of millions of people globally, yet access to therapy and safe medicine is typically limited, particularly in low-income nations. The world has gone a long way since the era of tranquillisers, but many experts feel a new wave of safe, fast-acting, and economical medicines is urgently required. 

As Ritchie and Acisu continue, progress over the last fifty years has saved countless lives; yet, the future of anxiety care depends on reigniting medical innovation and decreasing the stigma that keeps so many people silent.